Vanguard Group’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,574,979
| Closed | -$1.97M | – | 4698 |
|
|
2022
Q1 | $1.97M | Buy |
1,574,979
+100
| +0% | +$109 | ﹤0.01% | 3965 |
|
|
2021
Q4 | $1.83M | Buy |
1,574,879
+11,778
| +0.8% | +$17.6K | ﹤0.01% | 4079 |
|
|
2021
Q3 | $3M | Buy |
1,563,101
+24,638
| +2% | +$48.5K | ﹤0.01% | 3914 |
|
|
2021
Q2 | $3.6M | Sell |
1,538,463
-78,581
| -5% | -$189K | ﹤0.01% | 3758 |
|
|
2021
Q1 | $4.38M | Buy |
1,617,044
+6,218
| +0.4% | +$18.4K | ﹤0.01% | 3598 |
|
|
2020
Q4 | $3.9M | Sell |
1,610,826
-7,860
| -0.5% | -$17.9K | ﹤0.01% | 3467 |
|
|
2020
Q3 | $3.71M | Buy |
1,618,686
+834,718
| +106% | +$2.19M | ﹤0.01% | 3289 |
|
|
2020
Q2 | $1.8M | Buy |
783,968
+12,546
| +2% | +$28.9K | ﹤0.01% | 3458 |
|
|
2020
Q1 | $1.33M | Sell |
771,422
-500
| -0.1% | -$1.01K | ﹤0.01% | 3421 |
|
|
2019
Q4 | $1.6M | Hold |
771,922
| – | – | ﹤0.01% | 3510 |
|
|
2019
Q3 | $2.24M | Buy |
771,922
+20,545
| +3% | +$70.1K | ﹤0.01% | 3417 |
|
|
2019
Q2 | $2.95M | Buy |
751,377
+584,821
| +351% | +$3.05M | ﹤0.01% | 3353 |
|
|
2019
Q1 | $786K | Buy |
166,556
+3,692
| +2% | +$18.3K | ﹤0.01% | 3690 |
|
|
2018
Q4 | $374K | Sell |
162,864
-104,552
| -39% | -$520K | ﹤0.01% | 3792 |
|
|
2018
Q3 | $1.67M | Buy |
267,416
+1,672
| +0.6% | +$8.82K | ﹤0.01% | 3588 |
|
|
2018
Q2 | $1.82M | Sell |
265,744
-14,790
| -5% | -$111K | ﹤0.01% | 3530 |
|
|
2018
Q1 | $2.36M | Buy |
280,534
+177,303
| +172% | +$1.47M | ﹤0.01% | 3404 |
|
|
2017
Q4 | $958K | Sell |
103,231
-15,350
| -13% | -$154K | ﹤0.01% | 3619 |
|
|
2017
Q3 | $1.39M | Buy |
118,581
+11,486
| +11% | +$436K | ﹤0.01% | 3501 |
|
|
2017
Q2 | $4.47M | Buy |
107,095
+13,098
| +14% | +$631K | ﹤0.01% | 3125 |
|
|
2017
Q1 | $4.58M | Buy |
93,997
+9,632
| +11% | +$376K | ﹤0.01% | 3084 |
|
|
2016
Q4 | $2.78M | Sell |
84,365
-1,383
| -2% | -$45.5K | ﹤0.01% | 3248 |
|
|
2016
Q3 | $3.51M | Buy |
85,748
+3,684
| +4% | +$145K | ﹤0.01% | 3165 |
|
|
2016
Q2 | $2.69M | Buy |
82,064
+7,132
| +10% | +$261K | ﹤0.01% | 3256 |
|
|
2016
Q1 | $4.64M | Buy |
74,932
+956
| +1% | +$30.4K | ﹤0.01% | 2990 |
|
|
2015
Q4 | $3.12M | Buy |
73,976
+8,952
| +14% | +$427K | ﹤0.01% | 3214 |
|
|
2015
Q3 | $3.56M | Buy |
65,024
+24,607
| +61% | +$2.44M | ﹤0.01% | 3122 |
|
|
2015
Q2 | $4.44M | Buy |
40,417
+7,315
| +22% | +$679K | ﹤0.01% | 3066 |
|
|
2015
Q1 | $3.14M | Buy |
33,102
+18,671
| +129% | +$1.32M | ﹤0.01% | 3215 |
|
|
2014
Q4 | $808K | Buy |
14,431
+232
| +2% | +$15.8K | ﹤0.01% | 3599 |
|
|
2014
Q3 | $1.03M | Buy |
14,199
+2,862
| +25% | +$313K | ﹤0.01% | 3497 |
|
|
2014
Q2 | $1.7M | Buy |
11,337
+305
| +3% | +$46.3K | ﹤0.01% | 3328 |
|
|
2014
Q1 | $1.61M | Buy |
+11,032
| New | +$1.35M | ﹤0.01% | 3314 |
|
Other funds holding GNCA
Vanguard Group's GNCA Position: Q2 2022 in Review
Vanguard Group sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 1,574,979 shares — an estimated $1.97M sold.
Vanguard Group first reported a position in GNCA in Q1 2014 and held it in 33 quarters. The position peaked at $4.64M in Q1 2016. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.
- Vanguard Group reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
- Vanguard Group sold 1,574,979 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $1.97M.
- Vanguard Group first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 33 quarters.
- Vanguard Group's Genocea Biosciences, Inc. position peaked at $4.64M in Q1 2016.
- 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.
Based on Vanguard Group's 13F filing for Q2 2022, filed 12 Aug 2022.